ABSTRACT
ICRU Report 38 provided guidelines for recording and reporting dose points in adjacent normal tissues (bladder and rectum) and representative for the lymphatic system during the use of either low-dose-rate (LDR) or high-dose-rate (HDR) intracavitary BT (ICBT) for the treatment of cervical cancer. Along with information contained in ICRU Report 29 (ICRU 1978), there was a rational basis for dose calculation, recording, and reporting during both fractionated pelvic external beam radiotherapy (EBRT) and ICBT for the treatment of cervical cancer and other gynecologic malignancies.
